Kurt Kuhlman, DO
Physical Medicine & Rehabilitation · Lima, OHNPI 1144201013
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,114 of the $45,981 with a category attached, or 80.7%. AbbVie accounts for 92.5% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2021 at $15,702 and has fallen 91.6% since, to $1,314 in 2025. Among physical medicine & rehabilitation clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 579 payments — averaging $79.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$43K
- Pfizer$594
- Amgen$378
- Merz North America, Inc.$244
- Upsher-smith Laboratories LLC$208
- Galderma Laboratories, L.p.$207
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$37,11481%
- Travel & lodging$1,4783%
- Food & beverage$7,27016%
- Education$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 334 | $42,542 |
| Pfizer | 41 | $594 |
| Amgen(2 entities) | 36 | $378 |
| Merz North America, Inc. | 13 | $244 |
| Upsher-smith Laboratories LLC | 13 | $208 |
| Galderma Laboratories, L.p. | 13 | $207 |
| Lilly USA, LLC | 14 | $203 |
| Biohaven Pharmaceutical Holding Company Ltd. | 22 | $199 |
| Merz Pharmaceuticals, LLC | 12 | $198 |
| Biohaven Pharmaceuticals, Inc. | 15 | $169 |
| Teva Pharmaceuticals USA, Inc. | 9 | $127 |
| Lundbeck LLC | 6 | $117 |
| Novo Nordisk | 5 | $83 |
| Impel Pharmaceuticals Inc. | 4 | $77 |
| Avanir Pharmaceuticals, Inc. | 5 | $62 |
| Ipsen Biopharmaceuticals, Inc | 3 | $61 |
| Supernus Pharmaceuticals, Inc. | 4 | $60 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Novartis | 4 | $52 |
| Arbor Pharmaceuticals, Inc. | 4 | $51 |
| Fidia Pharma USA Inc. | 3 | $46 |
| Currax Pharmaceuticals LLC | 3 | $46 |
| Vertex | 2 | $43 |
| Zyla Life Sciences, Inc. | 3 | $42 |
| Scilex Pharmaceuticals Inc. | 3 | $37 |
| Bioventus LLC | 1 | $20 |
| Shield Therapeutics Inc | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Promius Pharma LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,981 in reported general payments places this provider in the 95th percentile of 332 physical medicine & rehabilitation providers in Ohio.
See all physical medicine & rehabilitation providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 93 | $148,325 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $16,284 |
| LyricaPregabalin | 13 | $9,067 |
| XeominIncobotulinumtoxina | 12 | $6,633 |
| Pregabalin | 193 | $5,012 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 185 | $4,316 |
| Gabapentin | 92 | $2,451 |
| Duloxetine Hcl | 80 | $1,711 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 70 | $1,252 |
| Tizanidine Hcl | 39 | $1,154 |
| Tramadol Hcl | 132 | $1,115 |
| Np ThyroidThyroid,pork | 20 | $1,025 |
| Topiramate | 83 | $968 |
| Celecoxib | 16 | $810 |
| Sumatriptan Succinate | 20 | $560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $42,542 | $148,32593 claims |
| PfizerLyrica | $594 | $9,06713 claims |
| Merz North America, Inc.Xeomin | $244 | $6,63312 claims |
| Upsher-smith Laboratories LLCTopiramate | $208 | $96883 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 332 physical medicine & rehabilitation providers in Ohio.
Other physical medicine & rehabilitation in Lima
- Derik ScribnerLima$4K
- Michael BariaLewis Center$175K
- Kathryn MosherAkron$121K
- Marc OrlandoCincinnati$114K
- Aileen PadillaPerrysburg$73K
- Jeffrey StrakowskiColumbus$59K
- Francois BethouxCleveland$39K
- Caitlin StuberColumbus$33K
- Francesco SammartinoDublin$32K
- Nikhil VermaColumbus$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.